In vivo transduction of HIV-1-derived lentiviral particles engineered for macrolide-adjustable transgene expression
作者： Barbara Mitta , Cornelia C. Weber , Martin Fussenegger
DOI: 10.1002/JGM.798
关键词:
摘要: Background The molecular merger of latest-generation transduction technologies with advanced transgene control modalities may foster decisive advances in therapeutic reprogramming somatic cell phenotypes. Methods We have engineered self-inactivating HIV-1-based lentiviral expression vectors for reversible macrolide-adjustable expression. Results Lentiviral particles macrolide-responsive human vascular endothelial growth factor 121 (VEGF121) compared favourably isogenic streptogramin- and tetracycline-responsive configurations showed excellent growth-factor fine-tuning following into a variety mammalian lines different primary cells. Chicken embryos transduced macrolide-controlled VEGF121 production exhibited dose-dependent neovascularization exemplified lentivector-delivered transcription vivo. Conclusions Macrolide-adjustable lentivectors enable robust precise vitro vivo which give future gene therapy trials new impetus. Copyright © 2005 John Wiley & Sons, Ltd.
sci-hub.se 参考文章(45)
An Van Damme, Marinee Chuah, Désiré Collen, Thierry VandenDriessche, Onco-retroviral and lentiviral vector-based gene therapy for hemophilia: preclinical studies. Seminars in Thrombosis and Hemostasis. ,vol. 30, pp. 185- 195 ,(2004) , 10.1055/S-2004-825632
MacGregor Rr, Clinical protocol. A phase 1 open-label clinical trial of the safety and tolerability of single escalating doses of autologous CD4 T cells transduced with VRX496 in HIV-positive subjects. Human Gene Therapy. ,vol. 12, pp. 2028- 2029 ,(2001)
Wilfried Weber, Martin Fussenegger, Inducible gene expression in mammalian cells and mice. Methods of Molecular Biology. ,vol. 267, pp. 451- 466 ,(2004) , 10.1385/1-59259-774-2:451
BORO DROPULIC, Lentivirus in the clinic. Molecular Therapy. ,vol. 4, pp. 511- 512 ,(2001) , 10.1006/MTHE.2001.0501
P F Lewis, M Emerman, Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. Journal of Virology. ,vol. 68, pp. 510- 516 ,(1994) , 10.1128/JVI.68.1.510-516.1994
Roland W Herzog, Valder R Arruda, Update on gene therapy for hereditary hematological disorders Expert Review of Cardiovascular Therapy. ,vol. 1, pp. 215- 232 ,(2003) , 10.1586/14779072.1.2.215
Lili Bao, Vijayendra Jaligam, Xian-Yang Zhang, Robert H. Kutner, Stephen P. Kantrow, Jakob Reiser, Stable Transgene Expression in Tumors and Metastases After Transduction with Lentiviral Vectors Based on Human Immunodeficiency Virus Type 1 Human Gene Therapy. ,vol. 15, pp. 445- 456 ,(2004) , 10.1089/10430340460745775
Emmanuel Richard, Fabien Géronimi, Magalie Lalanne, Cécile Ged, Isabelle Redonnet-Vernhet, Isabelle Lamrissi-Garcia, Stanton L Gerson, Hubert de Verneuil, François Moreau-Gaudry, A bicistronic SIN-lentiviral vector containing G156A MGMT allows selection and metabolic correction of hematopoietic protoporphyric cell lines. Journal of Gene Medicine. ,vol. 5, pp. 737- 747 ,(2003) , 10.1002/JGM.407
J K Koponen, H Kankkonen, J Kannasto, T Wirth, W Hillen, H Bujard, S Ylä-Herttuala, Doxycycline-regulated lentiviral vector system with a novel reverse transactivator rtTA2S-M2 shows a tight control of gene expression in vitro and in vivo. Gene Therapy. ,vol. 10, pp. 459- 466 ,(2003) , 10.1038/SJ.GT.3301889
Seppo Ylä-Herttuala, John F Martin, Cardiovascular gene therapy. The Lancet. ,vol. 355, pp. 213- 222 ,(2000) , 10.1016/S0140-6736(99)04180-X